The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its 4-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes.
CeQur®, a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today announced the successful close of a $120 million financing round. This significant investment underscores the confidence in CeQur’s mission to simplify the lives of people managing diabetes.
The funds will support the continued commercial expansion of CeQur Simplicity, the company’s innovative 4-day wearable insulin delivery device. CeQur will continue to grow its Sales Force and expand its Clinical team to ensure that more people living with diabetes can benefit from convenient, discreet, and injection-free dosing.
“We are grateful for the support of our investors as we accelerate our mission to transform diabetes care,” said Brad Paddock, President and CEO of CeQur. “This financing will enable us to reach more patients, expand our commercial footprint, and continue innovating solutions that simplify mealtime insulin management”, said Mike Rubino, CFO of CeQur.
CeQur has seen growing adoption of its CeQur Simplicity patch, a discreet, easy-to-use bolus insulin delivery solution, with over 6,000 patients currently using the device.
CeQur continues to increase and improve pharmacy access. In addition to the more than two thirds of commercially insured patients on formulary, CeQur has reached agreements with numerous Medicare Part-D and State Medicaid programs. Overall, better than 80% of all claims are being covered as a pharmacy benefit. The average copay is less than $45/month.
Related to manufacturing, CeQur’s 40,000 sq/ft automated cleanroom facility completed all of its qualifications in Q4 2024. The facility is scheduled to manufacture commercial product in 2025.